As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and …
Market Samachar is a news aggregator. This article was originally published by Nature.com. Tap the button above to read the full story on their site.